Antimicrobial peptides, disease severity and exacerbations in bronchiectasis.
Oriol SibilaLídia PereaElisabet CantóAmelia ShoemarkDiane CassidyAlexandria Holly SmithGuillermo Suarez-CuartinAna Rodrigo-TroyanoHolly R KeirMartina OrianoSamantha OngSilvia VidalFrancesco BlasiStefano AlibertiJames D ChalmersPublished in: Thorax (2019)
Patients with bronchiectasis showed dysregulated sputum AMP levels, characterised by elevated LL-37 and reduced SLPI levels in the frequent exacerbator phenotype. Elevated LL-37 and reduced SLPI levels are associated with Pseudomonas aeruginosa infection and can predict future risk of exacerbations in bronchiectasis.